Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 690, Issue 1-2, 2010, Pages 95-101

  Moschen, Alexander R ^a   Geiger, Sabine ^a   Gerner, Romana ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bone mineral density; Inflammatory bowel disease; NAMPT; Osteoclast; PBEF; Visfatin

Indexed keywords

CATHEPSIN K; COLONY STIMULATING FACTOR 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MARROW CELL; BONE METABOLISM; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; LUMBAR SPINE; MALE; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIGENS, CD14; BONE DENSITY; BONE DISEASES; CELL DIFFERENTIATION; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MONOCYTES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOCLASTS;

EID: 77955282709     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.06.012     Document Type: Article

References (37)

1. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
2. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
3. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 2006, 24:33-63.
4. Henderson S., Hoffman N., Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2006, 101:119-123.
5. Tilg H., Moschen A.R., Kaser A., Pines A., Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008, 57:684-694.
6. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F., Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 2002, 110:1419-1427.
7. Ashcroft A.J., Cruickshank S.M., Croucher P.I., Perry M.J., Rollinson S., Lippitt J.M., Child J.A., Dunstan C., Felsburg P.J., Morgan G.J., Carding S.R. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003, 19:849-861.
8. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 2002, 20:795-823.
9. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994, 14:1431-1437.
10. Luk T., Malam Z., Marshall J.C. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol. 2008, 83:804-816.
11. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 2001, 26:107-117.
12. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., Marshall J.C. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 2004, 113:1318-1327.
13. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 2002, 32:3225-3234.
14. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H. Visfatin, an adipocytokine with pro-inflammatory and immunomodulating properties. J. Immunol. 2007, 178:1748-1758.
15. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin. Sci. (Lond.) 2008, 114:275-288.
16. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, World Health Organ Tech. Rep. Ser. 843 (1994) 1-129.
17. Kim N., Kadono Y., Takami M., Lee J., Lee S.H., Okada F., Kim J.H., Kobayashi T., Odgren P.R., Nakano H., Yeh W.C., Lee S.K., Lorenzo J.A., Choi Y. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 2005, 202:589-595.
18. Felix R., Cecchini M.G., Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990, 127:2592-2594.
19. Kim N., Odgren P.R., Kim D.K., Marks S.C., Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10905-10910.
20. Ye S.Q., Simon B.A., Maloney J.P., Zambelli-Weiner A., Gao L., Grant A., Easley R.B., McVerry B.J., Tuder R.M., Standiford T., Brower R.G., Barnes K.C., Garcia J.G. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am. J. Respir. Crit. Care Med. 2005, 171:361-370.
21. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R.E., Gay S., Kyburz D. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007, 56:2829-2839.
22. Yilmaz M.I., Saglam M., Carrero J.J., Qureshi A.R., Caglar K., Eyileten T., Sonmez A., Cakir E., Yenicesu M., Lindholm B., Stenvinkel P., Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 2008, 23:959-965.
23. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., Brunkan C.S., Wolberger C., Imai S., Tabas I. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008, 283:34833-34843.
24. Lee W.J., Wu C.S., Lin H., Lee I.T., Wu C.M., Tseng J.J., Chou M.M., Sheu W.H. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int. J. Obes. (Lond.) 2009, 33:465-472.
25. Busso N., Karababa M., Nobile M., Rolaz A., Van Gool F., Galli M., Leo O., So A., De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 2008, 3:e2267.
26. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P.J., Peschon J.J., Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13:2412-2424.
27. Moschen A.R., Kaser A., Enrich B., Ludwiczek O., Gabriel M., Obrist P., Wolf A.M., Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005, 54:479-487.
28. Peng X.D., Xie H., Zhao Q., Wu X.P., Sun Z.Q., Liao E.Y. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin. Chim. Acta 2008, 387:31-35.
29. Pfeilschifter J., Chenu C., Bird A., Mundy G.R., Roodman G.D. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J. Bone Miner. Res. 1989, 4:113-118.
30. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000, 106:1481-1488.
31. Kung Sutherland M.S., Lipps S.G., Patnaik N., Gayo-Fung L.M., Khammungkune S., Xie W., Brady H.A., Barbosa M.S., Anderson D.W., Stein B. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF. Cytokine 2003, 23:1-14.
32. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., Manolagas S.C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257:88-91.
33. Mabilleau G., Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE 2009, 4:e4173.
34. Gao Y., Grassi F., Ryan M.R., Terauchi M., Page K., Yang X., Weitzmann M.N., Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 2007, 117:122-132.
35. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K., Nakamura K., Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
36. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
37. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.